Antares Pharma, Inc. (NASDAQ:ATRS) today announced the appointment of
David H. Bergstrom Ph.D. to the position of Senior Vice President of
Pharmaceutical Development. Dr. Bergstrom is an experienced, operations
focused executive with a leadership background in large, small and
semi-virtual pharmaceutical companies as well as in the contract product
development and manufacturing industry. He received his Ph.D. in
Pharmaceutics from the University of Utah, Salt Lake City, Utah.
Dr. Bergstrom comes to Antares Pharma from Advantar Laboratories where
he was the Executive Vice President and Chief Operating Officer. Prior
to joining Advantar, he was the Senior Vice President and COO for
NovaDel Pharmaceuticals. Dr. Bergstrom previously served as Senior Vice
President and General Manager of the Pharmaceutical Development business
of Cardinal Health, Inc. Prior to Cardinal Health, Dr. Bergstrom served
as Vice President of Pharmaceutical and Chemical Development at Guilford
Pharmaceuticals and also served in senior positions in preclinical
development and pharmaceutical and analytical development at
Hoechst-Roussel Pharmaceuticals, Inc., predecessor companies of
Sanofi-Aventis Pharmaceuticals, Inc. Prior to that, Dr. Bergstrom worked
in pharmaceutical development at CIBA-Geigy Pharmaceuticals, Inc.
“We are very pleased to welcome Dr. Bergstrom to the Antares team,” said
Paul K. Wotton, Ph.D., President and Chief Executive Officer. “David has
a proven track record as a leader of product development teams and has
worked on multiple FDA approved products including 505B2 drug/device
combination programs. His broad product development expertise will help
drive our pipeline initiative and insure that we continue to execute our
programs aggressively and expedite future product launches such as Quick
Shot™ testosterone and QS M.”
About Antares Pharma
Antares Pharma focuses on self-administered parenteral pharmaceutical
products and topical gel-based medicines. The Company has received
marketing approval from the U.S. Food and Drug Administration for
OTREXUP™ (methotrexate) injection for the treatment of adults with
severe active rheumatoid arthritis, children with active polyarticular
juvenile idiopathic arthritis and adults with severe recalcitrant
psoriasis. Antares Pharma is also developing VIBEX® QS T for
testosterone replacement therapy. The Company's technology platforms
include VIBEX® disposable Medi-Jet, disposable multi-use pen
injectors and Vision™ reusable needle-free injectors marketed as Tjet®
and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva)
and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has
a multi-product deal with Teva that includes Tev-Tropin®
[somatropin (rDNA origin) for injection] human growth hormone (hGH),
VIBEX® epinephrine and several other products. Antares
Pharma’s partnership with Ferring includes Zomacton® hGH
(somatropin) injection. In the U.S. Antares has received FDA approval
for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder
that is marketed by Actavis. Elestrin® (estradiol gel) is FDA
approved for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, and is marketed in the U.S. by Meda Pharma.
Antares Pharma has two facilities in the U.S. The Parenteral Products
Group located in Minneapolis, Minnesota directs the manufacturing and
marketing of the Company’s reusable needle-free injection devices and
related disposables, and develops its disposable pressure-assisted
Medi-Jet and pen injector systems. The Company’s corporate office and
Product Development and Commercial Groups are located in Ewing, New
Jersey.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These statements are indicated by the
words “may,” “will,” “plans,” “intends,” “believes,” “expects,”
“anticipates,” “potential,” “could,” “would,” “should,” and similar
expressions. Such forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that may
cause actual results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include, among
others, changes in revenue growth and difficulties or delays in the
commercial launch of OTREXUP™, market acceptance by physicians and
patients of new products, delays in product development and changes or
delays in the regulatory process for existing or new product candidates.
In addition, the Quick Shot™ testosterone and the QS M
products referred to in this press release have not yet been approved by
the FDA, and the commercialization of Quick Shot testosterone and QS M
are dependent on the FDA approving these products. Additional
information concerning these and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Annual Report on Form 10-K for the year ended December 31,
2012, and in the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors not
to place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof, and
the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the
date of this press release, except as required by law.
Copyright Business Wire 2013